Patents Assigned to Protagonist Therapeutics, Inc.
  • Compositions of peptide inhibitors of Interleukin-23 receptor
    Patent number: 11939361
    Abstract: The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: March 26, 2024
    Assignees: Janssen Pharmaceutica NV, Protagonist Therapeutics, Inc.
    Inventors: Giustino Di Pretoro, Dajun Sun, Gopal Rajan, Geraldine Broeckx, Nathalie Mertens, Shu Li, Felix Lai, Mohammad Masjedizadeh, Anne M. Fourie, Beverly Knight, David Polidori, Santhosh Francis Neelamkavil, Nishit Modi, Ashok Bhandari, Xiaoli Cheng
  • CONJUGATED HEPCIDIN MIMETICS
    Publication number: 20240066131
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 28, 2021
    Publication date: February 29, 2024
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas BOURNE, Ashok BHANDARI, Jie ZHANG, Brian Troy FREDERICK, Mark Leslie SMYTHE
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 11884748
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: January 30, 2024
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Thomas Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • CONJUGATED HEPCIDIN MIMETICS
    Publication number: 20240018189
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 18, 2024
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas BOURNE, Ashok BHANDARI, Jie ZHANG, Brian Troy FREDERICK, Mark Leslie SMYTHE
  • Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
    Patent number: 11845808
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: December 19, 2023
    Assignees: Janssen Biotech, Inc., Protagonist Therapeutics, Inc.
    Inventors: Chengzao Sun, Brian Troy Frederick, Sandeep Somani, Gregory Thomas Bourne, Raymond Patch, Ashok Bhandari
  • ?4?7 thioether peptide dimer antagonists
    Patent number: 11840581
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: December 12, 2023
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • Hepcidin analogues and uses thereof
    Patent number: 11807674
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: November 7, 2023
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Conjugated hepcidin mimetics
    Patent number: 11753443
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: September 12, 2023
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas Bourne, Ashok Bhandari, Brian Troy Frederick, Jie Zhang, Adam Stephenson, Mark Leslie Smythe, Roopa Taranath, David Liu
  • PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES
    Publication number: 20230129095
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Application
    Filed: January 14, 2021
    Publication date: April 27, 2023
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok BHANDARI, Brian Troy FREDERICK, Tran Trung TRAN, Gregory Thomas BOURNE
  • Analogues of hepcidin mimetics with improved in vivo half lives
    Patent number: 11472842
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: October 18, 2022
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas Bourne, Mark Leslie Smythe, Brian Troy Frederick, Ashok Bhandari
  • ?4?7 peptide monomer and dimer antagonists
    Patent number: 11111272
    Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: September 7, 2021
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
  • Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
    Patent number: 11041000
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: June 22, 2021
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Brian Troy Frederick, David Clifford Sullivan
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 10941183
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 9, 2021
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Thomas Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • ?4?7 thioether peptide dimer antagonists
    Patent number: 10626146
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: April 21, 2020
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • Hepcidin analogues and uses thereof
    Patent number: 10501515
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 10, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Hepcidin analogues and uses thereof
    Patent number: 10442846
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 15, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Methods for synthesizing ?4?7 peptide antagonists
    Patent number: 10407468
    Abstract: The present invention provides methods of making ?4?7 peptide monomer and dimer antagonists. Methods of the present invention include solid phase and solution phase methods, as well as synthesis via condensation of smaller peptide fragments. Methods of the present invention further include methods directed to the synthesis of peptides comprising one or more penicillamine residues.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: September 10, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Suresh Kumar Manthati, Mukund M. Mehrotra, Sampath-Kumar Anandan, Dinesh V. Patel
  • Cyclic monomer and dimer peptides having integrin antagonist activity
    Patent number: 10301371
    Abstract: The invention relates to C to N cyclized (C-N cyclic) monomer and dimer peptide molecules, as well as peptide dimers which are connected by linker moieties at the N terminus and the C terminus of each peptide subunit, which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 28, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede
  • Opioid agonist peptides and uses thereof
    Patent number: 10278957
    Abstract: The invention is directed to opioid agonist peptides and their use.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: May 7, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Sampath Kumar Anandan, Jie Zhang, Ashok Bhandari, Gregory Thomas Bourne, Brian Troy Frederick, Larry C. Mattheakis, David Liu
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 10196424
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: February 5, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Bourne, Ashok Bhandari, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu